Agilent/$A

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Agilent

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Ticker

$A
Sector

Primary listing

NYSE

Employees

18,000

Agilent Metrics

BasicAdvanced
$39B
32.35
$4.28
1.26
$0.98
0.72%

What the Analysts think about Agilent

Analyst ratings (Buy, Hold, Sell) for Agilent stock.

Bulls say / Bears say

Revenue for Q3 FY25 rose 10.1% year-over-year to $1.74 billion, surpassing guidance and prompting Agilent to raise its full-year revenue outlook to $6.91–6.93 billion (+6.2% to +6.5%), underscoring robust demand across segments and geographies (Agilent)
GAAP EPS for Q3 FY25 increased 22% year-over-year to $1.18, demonstrating strong profitability improvements from the Ignite transformation despite a challenging macro backdrop (Agilent)
The Life Sciences and Diagnostics Markets Group achieved 14% reported revenue growth in Q3 FY25 to $670 million, highlighting sustained strength in high-margin diagnostics and genomics end markets (Agilent)
GAAP net income in Q2 FY25 fell 29% year-over-year to $215 million (EPS $0.75), reflecting volatility from transformation investments and signaling potential earnings swings ahead (Agilent)
Agilent noted a “full quarter of the dynamic tariff environment” in Q3, indicating persistent input-cost pressures from trade tensions that may constrain margins if not resolved (Agilent)
Chinese pharma R&D firms are increasingly sourcing reagents from domestic suppliers to cut costs and delivery times, threatening to erode Agilent’s CrossLab consumables revenues in its key market (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

Agilent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agilent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $A

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs